Navigation Links
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
Date:1/5/2009

s transaction represents a unique opportunity for us to achieve these goals. The combined company will market nine products through three specialty sales forces and have the capability to develop innovative new therapies using a novel drug delivery technology. We believe this will make Endo a stronger competitor, a more valuable health care supplier and a more successful company."

Indevus chairman and chief executive officer, Glenn L. Cooper, M.D., stated, "This transaction allows us to capture significant value for our shareholders and create new value for patients, physicians and shareholders of both companies under Endo's leadership. We believe Endo's proven commercial capabilities, targeted approach to medical marketing and unique understanding of the changes taking place in health care delivery today will ensure the success of our current and future products. We welcome and fully support this acquisition."

Endo expects that the transaction will be dilutive to the company's earnings in 2009 and is targeted to become accretive to Endo's earnings in 2010. Endo expects to achieve up to $40 million in cost savings and will provide more complete financial guidance during its fourth quarter and full-year earnings conference call in February.

Novel Products and Drug-Delivery Technology

Endo currently markets proprietary and generic products for the treatment and management of pain. Indevus currently markets products to treat overactive bladder, prostate cancer and central precocious puberty and is pursuing regulatory approval of drugs to treat hypogonadism and bladder cancer.

Mr. Holveck noted, "In addition to the very successful drug, VANTAS(R), we are particularly excited about the opportunity to add three innovative drug therapies, SUPPRELIN(R) LA, NEBIDO(R) and octreotide implant, to our product portfolio. All three are intended to address significant patient needs in
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Grand Bahama (PRWEB) May 05, 2015 ... its Orthopedic Lifestyle Report today. The study was conducted ... conditions such as osteoarthritis and sports-related injuries ... pain and stiffness was the most prevalent symptom reported ... functionality such as walking, standing and bending over. Over ...
(Date:5/5/2015)... On May, 5, 2015, My Positive Perspective host Jason Deierlein ... for youngsters to do this summer. As the episode began, ... starting a summer camp and how is it going to ... Upon a Party and I come to children’s birthday parties ... We play games, sing, and dance and have a great ...
(Date:5/5/2015)... On April 8th, 2015, at the famous Avalon ... Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a daylong event organized ... placement in TV and film. , A gathering ... sound and socially conscious products and services, the EcoLuxe ... appearances at various awards ceremonies and festivals each year, ...
(Date:5/5/2015)... For the growing list of high temperature monitoring demands, ... data logger series is based on a compact, ... throughout exposure to high temperatures and submersion without compromise. ... storing up to 32,700 readings and feature a user replaceable ... longer. All data loggers in the HiTemp140 series can be ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Don’t have ... money for a fitness membership? Don’t know which workout ... these obstacles in order to help members achieve their ... Live Streaming Fitness, an educational, caused-based wellness company, today ... live streaming fitness classes led by certified trainers, nutritional ...
Breaking Medicine News(10 mins):Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3
... 11 Hope Solution, a 501-C3 nonprofit organization, is ... webcast telethon at Sojourner-Douglass College , located in ... 16th from 12noon to 6pm, and will raise money ... treatment options and dietary supplements.To view the Multimedia News ...
... offices and deserted restaurants are,a real possibility if the ... The public has been suffering from "gloom,fatigue" with constant ... threat,of this flu outbreak has been ignored. But this ... the year with dire results. Two of the EIU,s,top ...
... Africa,s healthcare markets are ... economic slowdown. Pressures from the global environment have ... resources.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"Countries that have been ... driven by commodity exports," says Frost & Sullivan ...
... Nearly all off-the-shelf liquid hand sanitizers and hand wipes are alcohol ... prevent. Alcohol dries the skin causing cracks that open a direct ... non-toxic and non-alcohol hand sanitizers. , ... Erath, Louisiana ...
... A new analysis finds that a considerable number of ... financial connections to pharmaceutical companies. Published in the June ... journal of the American Cancer Society, the study indicates ... report biased results that are favorable to companies. , ...
... in blood vessels from triggering a later-stage, frequently lethal ... in the journal Nature Medicine . By eliminating ... (CypA) from a strain of mice, researchers were able ... , The aorta is the main artery carrying ...
Cached Medicine News:Health News:Not All Gloomy for African Healthcare Markets: Frost & Sullivan Finds Potential Despite the Recession 2Health News:Not All Gloomy for African Healthcare Markets: Frost & Sullivan Finds Potential Despite the Recession 3Health News:Q-Based Healthcare Warns: Hand Sanitizers Increase Risk of Swine Flu Exposure 2Health News:Q-Based Healthcare Warns: Hand Sanitizers Increase Risk of Swine Flu Exposure 3Health News:Review finds conflicts of interest in many cancer studies 2Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 2Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 3Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 4
(Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
(Date:5/5/2015)... 5, 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: ... that specializes in developing safer, more effective cannabis-based ... investor, and Non-Executive Director, Peter Mountford , ... with primary responsibility for the European markets. ... leverage his previous success in the emerging field ...
(Date:5/4/2015)... May 4, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... financial results for the first quarter ended March 31, ... "Following our equity offering in February, ... we are in a strong financial position to ...
Breaking Medicine Technology:InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8
... the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a 92 ... treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical studies,recently ...
... Groundbreaking 2002 ... ... study reveals that,coiling, a minimally invasive procedure to treat aneurysms in ... treatment in those aneurysms considered "untouchable" by the,traditional surgical option. One ...
Cached Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Adson periosteal elevators, No. 4 straight, semi-sharp edge, blade width 5/16" (8 mm), length 6 1/2" (165 mm)....
West 2 periosteal elevators....
Medicine Products: